ESR1 and breast carcinoma: The introduction of very sensitive technologies like droplet digital polymerase chain reaction (PCR) (ddPCR) have enabled the detection of ESR1 mutations in plasma cell free DNA (cfDNA) and in the CTC-derived DNA of breast cancer patients [21,22,23].